◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 1167

Jacobio Pharmaceuticals Group Co., Ltd. (1167) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-10

Jacobio Pharmaceuticals Group Co., Ltd. (1167) operates in the Biotechnology industry and is headquartered in Beijing, China with about 67 employees. Its market capitalization is roughly CNY 4 billion. In the fiscal year ended 2025-12-31, 1167 reported CNY 54M in revenue and (CNY 146M) in net income.

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China.

Interactive charts & full statements →

1167 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 54MCNY 156MCNY 64MCNY 96M
Gross ProfitCNY 53MCNY 156MCNY 3MCNY 13M
Operating Income (EBIT)(CNY 166M)(CNY 203M)(CNY 408M)(CNY 474M)
Net Income(CNY 146M)(CNY 156M)(CNY 359M)(CNY 372M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1167 Free Cash Flow History

1167 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 1.3BCNY 1.4BCNY 1.5BCNY 1.6B
Total LiabilitiesCNY 534MCNY 436MCNY 387MCNY 292M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1167 viewer.

Other Companies in Biotechnology

← 1166All “0-9” companies1168 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.